Simao W. Huang

Hangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Correction: CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Correction: CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Journal: Leukemia
Published: August 10, 2026

Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.

Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.

Journal: JAMA oncology
Published: July 23, 2026

Long-Term Follow-Up of CD19 CAR-T for R/R B-NHL: Ki-67 as a Prognostic Factor for Sustained Remission.

Long-Term Follow-Up of CD19 CAR-T for R/R B-NHL: Ki-67 as a Prognostic Factor for Sustained Remission.

Journal: Transplantation and cellular therapy
Published: March 06, 2026

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Journal: Leukemia
Published: January 28, 2026

CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study.

CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study.

Journal: HLA
Published: November 23, 2025

Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.

Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.

Journal: Nature cancer
Published: July 12, 2025

Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.

Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.

Journal: Nature medicine
Published: April 18, 2025

Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

Journal: JAMA oncology
Published: April 17, 2025

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

Journal: Bone marrow transplantation
Published: April 12, 2025

Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.

Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.

Journal: Journal for immunotherapy of cancer
Published: March 06, 2025

Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result.

Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result.

Journal: Journal of advanced research
Published: November 16, 2024

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Journal: Experimental hematology & oncology
Published: October 16, 2024
Showing 1-12 of 21

Last Updated: 09/26/2026